Risk factor analysis and risk assessment model development for Crohn's disease with metabolic dysfunction-associated fatty liver disease in a Chinese population

Background Metabolic dysfunction-associated fatty liver disease (MASLD) frequently occurs as a hepatic complication in patients diagnosed with Crohn's disease (CD), influenced by numerous risk determinants. This study aimed to explore the clinical characteristics associated with MASLD in CD patients and to construct a tailored risk assessment model. Methods Patients with CD who were hospitalized at our gastroenterology unit between January 2021 and March 2025 were enrolled. Patients were divided into two groups based on hepatic ultrasonography, as well as cardiovascular metabolic risk assessment: MASLD and non-MASLD. Clinical variables, laboratory results, as well as histories of medication intake, were obtained for both groups. Putative risk factors were first identified in univariate analyses, further adjusted by least absolute shrinkage and selection operator (LASSO) regression. Multivariate logistic regression was finally performed to establish the risk assessment model, from which a nomogram was created. Model performance was assessed by the concordance index (C-index), calibration curve, and decision curve analysis (DCA). Internal validation was performed by bootstrap resampling (1,000 replicates) to obtain optimism-corrected performance estimates, Sensitivity analyses were performed to address incorporation bias. Result A total of 187 patients with CD were enrolled, among whom the MASLD prevalence was 20.9%. Multivariate logistic regression identified independent risk factors of MASLD, including age, body mass index (BMI), high-density lipoprotein (HDL), lactate dehydrogenase (LDH), and fecal calprotectin (FC). The model showed good discrimination for ultrasound-defined MASLD (C-index 0.915). The calibration curve demonstrated close correspondence between predicted probabilities and observed outcomes. Bootstrap validation yielded an optimism-corrected C-index of 0.900 (estimated optimism, 0.015), with an optimism-corrected calibration slope of 0.854 and intercept of −0.106, while DCA suggested potential net benefit across a wide threshold range. In sensitivity analyses, the model excluding BMI and HDL achieved an area under the receiver operating characteristic curve (AUC) of 0.804. Conclusion A nomogram incorporating age, BMI, HDL, LDH and FC showed promising performance in identifying ultrasound-defined MASLD in hospitalized Chinese patients with CD. External and prospective validation is required before the model can be used to guide further hepatic evaluation.

Authors

Institutions

Publication Details

Journal
Frontiers in Medicine
Published
2026-11-18
DOI
https://doi.org/10.3389/fmed.2026.1982320
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Risk factor analysis and risk assessment model development for Crohn's disease with metabolic dysfunction-associated fatty liver disease in a Chinese population

Keyu Jia, Jun Shen, Chen Ye, Shiying Yuan et al.
7 links
Frontiers in Medicine
Liver Disease Diagnosis and Treatment
article

Risk factor analysis and risk assessment model development for Crohn's disease with metabolic dysfunction-associated fatty liver disease in a Chinese population

Keyu Jia, Jun Shen, Chen Ye, Shiying Yuan, Yuqi Qiao, Xueyun Zhang
article en

Abstract

Background Metabolic dysfunction-associated fatty liver disease (MASLD) frequently occurs as a hepatic complication in patients diagnosed with Crohn's disease (CD), influenced by numerous risk determinants. This study aimed to explore the clinical characteristics associated with MASLD in CD patients and to construct a tailored risk assessment model. Methods Patients with CD who were hospitalized at our gastroenterology unit between January 2021 and March 2025 were enrolled. Patients were divided into two groups based on hepatic ultrasonography, as well as cardiovascular metabolic risk assessment: MASLD and non-MASLD. Clinical variables, laboratory results, as well as histories of medication intake, were obtained for both groups. Putative risk factors were first identified in univariate analyses, further adjusted by least absolute shrinkage and selection operator (LASSO) regression. Multivariate logistic regression was finally performed to establish the risk assessment model, from which a nomogram was created. Model performance was assessed by the concordance index (C-index), calibration curve, and decision curve analysis (DCA). Internal validation was performed by bootstrap resampling (1,000 replicates) to obtain optimism-corrected performance estimates, Sensitivity analyses were performed to address incorporation bias. Result A total of 187 patients with CD were enrolled, among whom the MASLD prevalence was 20.9%. Multivariate logistic regression identified independent risk factors of MASLD, including age, body mass index (BMI), high-density lipoprotein (HDL), lactate dehydrogenase (LDH), and fecal calprotectin (FC). The model showed good discrimination for ultrasound-defined MASLD (C-index 0.915). The calibration curve demonstrated close correspondence between predicted probabilities and observed outcomes. Bootstrap validation yielded an optimism-corrected C-index of 0.900 (estimated optimism, 0.015), with an optimism-corrected calibration slope of 0.854 and intercept of −0.106, while DCA suggested potential net benefit across a wide threshold range. In sensitivity analyses, the model excluding BMI and HDL achieved an area under the receiver operating characteristic curve (AUC) of 0.804. Conclusion A nomogram incorporating age, BMI, HDL, LDH and FC showed promising performance in identifying ultrasound-defined MASLD in hospitalized Chinese patients with CD. External and prospective validation is required before the model can be used to guide further hepatic evaluation.

Frontiers in MedicineVol. 13
Shanghai Jiao Tong University (CN), Renji Hospital (CN)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon